Newsletters


Filter by volume

Agenus on Twitter

Agenus Provides R&D Update & Second Quarter Financial Report investor.agenusbio.com/2020-08-06-Age…

Agenus to Present on Targeting Myeloid Cells in Tumor Microenvironment at the William Blair Biotech Focus 2020 Conference investor.agenusbio.com/2020-08-04-Age…

$AGEN R&D update & 2Q Earnings: - Registration plans for bal +/- zali - $AGEN/Betta partnership - AGEN1181 +/- bal (anti-PD-1) - iNKT cells for COVID-19 & cancer - AGEN1223 & AGEN2373 update - Myeloid cell targets (TIGIT(s)/novel) investor.agenusbio.com/2020-07-29-Age…

Agenus Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals investor.agenusbio.com/press-releases…

AGENUS NEWSLETTER: The immune system is complex. $AGEN's portfolio is designed to empower the body’s immune system to do its job – to cure disease. READ MORE: agenusbio.com/wp-content/upl…

test Twitter Media - AGENUS NEWSLETTER:  The immune system is complex.  $AGEN's portfolio is designed to empower the body’s immune system to do its job – to cure disease.  
READ MORE:  https://t.co/orDRXz2oSV https://t.co/uRrwf3uB9O

$AGEN files new shelf registration statement as current shelf nears expiry. sec.gov/Archives/edgar…

Agenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease Summit investor.agenusbio.com/2020-07-21-Age…

$AGEN optimal combos with allogeneic cell therapy (iNKT), checkpoint antibodies for cures in preclinical models resistant to anti-PD-1. @Agenus_Bio is well-positioned to deliver these combos from our proprietary pipeline. #AACR2020 #Cancer agenusbio.com/publications/#… twitter.com/Agenus_Bio/sta… Retweeted by Agenus Inc. ($AGEN)

At #AACR2020, $AGEN demonstrated potential for curative combinations with #celltherapy & #Checkpoint antibodies in models refractory to anti-PD-1. @Agenus_Bio proprietary pipeline is positioned to deliver these combos! #Immunotherapy #cancer

test Twitter Media - At #AACR2020, $AGEN demonstrated potential for curative combinations with #celltherapy & #Checkpoint antibodies in models refractory to anti-PD-1.  @Agenus_Bio proprietary pipeline is positioned to deliver these combos! #Immunotherapy #cancer https://t.co/mg1YfvtDqa

At #AACR2020 we @Agenus_Bio demonstrate the curative combination potential of our pipeline in models that are refractory to first generation IO therapies. $AGEN is best positioned to advance more effective combinations for cancer patients today. twitter.com/Agenus_Bio/sta… Retweeted by Agenus Inc. ($AGEN)

$AGEN Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020 investor.agenusbio.com/2020-06-22-Age…

Agenus and Betta Pharmaceuticals Enter Into a License Agreement for Balstilimab and Zalifrelimab in Greater China investor.agenusbio.com/2020-06-22-Age…

@Agentus_CellTX CEO Walter Flamenbaum & CTO Marc Van Dijk reveal proprietary allogeneic iNKTs have potential to treat solid tumors with antibody combos (with $AGEN CPIs) affordably. iNKTs are advancing in #COVID19 & #Cancer @RaymondJames #Healthcare conference Retweeted by Agenus Inc. ($AGEN)

Experts Drs. Marc Van Dijk & Walter Flamenbaum join cell therapy expert panel @RaymondJames Conference: #CellTherapy: Promise of the Next Generation.

test Twitter Media - Experts Drs. Marc Van Dijk & Walter Flamenbaum join cell therapy expert panel @RaymondJames Conference: #CellTherapy: Promise of the Next Generation. https://t.co/0KhTIb32uQ

$AGEN will host calls with investors to address your questions every Wednesday @4PM. To register, please call 781-674-4408. Retweeted by Agenus Inc. ($AGEN)

NEWSLETTER: #ASCO20 highlights and $AGEN pipeline of Fc engineered TIGIT & CTLA-4 with our plans to unlock value for patients with #Cancer agenusbio.com/wp-content/upl…

test Twitter Media - NEWSLETTER:  #ASCO20 highlights and  $AGEN pipeline of Fc engineered TIGIT & CTLA-4 with our plans to unlock value for patients with #Cancer https://t.co/cfbidxWZj1 https://t.co/EyMF2LLDAO

TUNE IN: Shoptalk Virtual Conference with @garo_armen Chairman and CEO at @Agenus_Bio, to discuss the future of retail based on progress in COVID-19 therapeutics and vaccines on June 11 1-1:45pm ET. twitter.com/shoptalk/statu…

FDA clears IND application for natural killer T-cell therapy @Agenus_Bio @Agentus_CellTX to treat #COVID19 - phase 1 trial to come bit.ly/2Ax2Rwscome bit.ly/2 Retweeted by Agenus Inc. ($AGEN)

FBR has informed callers to use 973-413-6102 twitter.com/Agenus_Bio/sta…